Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Sold by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. lessened its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 23.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 24,818 shares of the company’s stock after selling 7,501 shares during the period. Point72 Asia Singapore Pte. Ltd.’s holdings in Ginkgo Bioworks were worth $244,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. SG Americas Securities LLC acquired a new stake in shares of Ginkgo Bioworks in the fourth quarter valued at about $199,000. KBC Group NV acquired a new stake in shares of Ginkgo Bioworks in the fourth quarter valued at about $31,000. Forbes J M & Co. LLP lifted its stake in shares of Ginkgo Bioworks by 461.4% in the fourth quarter. Forbes J M & Co. LLP now owns 701,732 shares of the company’s stock valued at $6,891,000 after purchasing an additional 576,732 shares during the period. Palumbo Wealth Management LLC acquired a new stake in shares of Ginkgo Bioworks in the fourth quarter valued at about $144,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Ginkgo Bioworks in the fourth quarter valued at about $154,000. Institutional investors and hedge funds own 78.63% of the company’s stock.

Ginkgo Bioworks Stock Up 3.3%

Shares of NYSE DNA opened at $7.92 on Friday. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $5.00 and a 52 week high of $34.78. The firm has a 50-day moving average price of $7.17 and a 200 day moving average price of $9.06. The stock has a market capitalization of $459.75 million, a price-to-earnings ratio of -0.61 and a beta of 1.29.

Ginkgo Bioworks (NYSE:DNA) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.35). Ginkgo Bioworks had a negative net margin of 298.78% and a negative return on equity of 58.54%. The company had revenue of $48.32 million during the quarter, compared to analyst estimates of $38.70 million. Equities research analysts expect that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current fiscal year.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.